First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

ResearchMoz presents this most up-to-date research on "First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline".

The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma, with lymphomas the most prevalent. Due to a degree of crossover between hematological malignancies in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

The report assesses versatile and first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 477 first-in-class products.
Over the past 15 years, the treatment of hematological malignancies has changed significantly, thanks to the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

The first-in-class targets in the pipeline are numerous and varied. Cytokine signaling targets are the most common, with a total of 548 across all stages of development, followed by kinases. These target categories account for the majority of targeted immunotherapies, which are the primary focus of current development activity within oncology. The other target families have far fewer first-in-class and versatile first-in-class products, reflecting the strong interest and potential versatility of cancer immunotherapies.

Scope

• With 1,474 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future hematological cancer market?
• There are 477 first-in-class products in the hematological cancer pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
• The majority of first-in-class products were identified to be in development for multiple indications. Are versatile products likely to play a key role in the future treatment of hematological cancer?
• Analysis of the history of strategic consolidations revealed an increasing amount of deal activity and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1135805

Reasons to buy

• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available. 
• Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market. 
• Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers. 
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail. 
• Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are being developed for.
• Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 Large Therapy Area with a High Degree of Pathophysiological Crossover 5
2.2 High Degree of First-in-Class Programs and Program Versatility in a Strong Pipeline 5
2.3 Sharp Increase in Deal Activity in Recent Years 5

3 The Case for Innovation in the Hematological Cancer Market 6
3.1 Growing Number of Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 9
3.6 GBI Research Report Guidance 9

Browse More Details @ http://www.researchmoz.us/frontier-pharma-firstinclass-innovation-in-hematological-cancers-cytokine-signaling-and-kinase-targeted-immunotherapies-dominate-a-large-and-highly-versatile-pipeline-report.html

Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma

Researchmoz added Most up-to-date research on "Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma" to its huge collection of research reports.

Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later-stage disease is largely reliant on cytotoxic chemotherapy regimens.

A highly active ovarian cancer pipeline contains an array of diverse molecule types and molecular targets, in contrast to the market. With the diversity in the pipeline, there is hope that innovative products can make it to market to provide patients with greater therapeutic options, while meeting unmet needs within ovarian cancer. There are 179 ovarian cancer pipeline products associated with a first-in-class molecular target representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. Such a diverse and innovative pipeline implies that approaches to ovarian cancer treatment are changing and first-in-class development is playing a significant role in this.

Scope

Chemotherapy based regimens continue to dominate the market, which has seen few new entrants over the past decade. Lynparza (olaparib) is a key new entrant; however it is only effective in a small patient subset.

• What survival benefits do current therapies provide?
• What are the current unmet needs that the pipeline needs to address?
• The pipeline places increased focus on targeted therapies, including a large number of therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
• What potential do mAbs have in ovarian cancer treatment?
• Will pipeline diversity translate to clinically and commercially successful therapies?
• How are common target families, such as intracellular signal transduction associated with pathophysiology?
• 52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages.
• Do first-in-class products show strong progression into the later stages?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=499491

• Why is the greatest number of first-in-class products seen in signal transduction?
• First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways
• How well are first-in-class targets, such as Notch, aligned to known disease causing pathways?
• Which targets are specifically found in early-stage development?
• What is the industry-wide interest in these targets?
• Co-development deals for first-in-class products are typically higher value than non-first-in-class counterparts.
• To what extent does first-in-class status influence deal value and phase?
• Can biologics command a greater deal value than other molecule types?

Reasons to buy

This report will allow you to 

• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
• Visualize the composition of the ovarian cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
• Analyze the ovarian cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating ovarian cancer.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=499491